VVM
PASG icon

Versant Venture Management’s Passage Bio PASG Stock Holding History

Versant Venture Management’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-201,321
Closed -$3.2M – 8
2024
Q2 		$3.2M Sell
201,321
-46,667
-19% -$1.14M 4.14% 6
2024
Q1 		$6.7M Hold
247,988
– – 6.49% 6
2023
Q4 		$5.01M Hold
247,988
– – 1.29% 5
2023
Q3 		$3.26M Hold
247,988
– – 1.73% 6
2023
Q2 		$4.67M Hold
247,988
– – 5.54% 6
2023
Q1 		$4.75M Hold
247,988
– – 9.9% 3
2022
Q4 		$6.84M Hold
247,988
– – 14.16% 3
2022
Q3 		$6.2M Hold
247,988
– – 10.57% 3
2022
Q2 		$11.7M Hold
247,988
– – 17.94% 2
2022
Q1 		$15.4M Hold
247,988
– – 15.35% 2
2021
Q4 		$31.5M Hold
247,988
– – 16.84% 3
2021
Q3 		$49.4M Hold
247,988
– – 20.45% 2
2021
Q2 		$65.7M Hold
247,988
– – 21.76% 2
2021
Q1 		$86.7M Buy
+247,988
New +$106M 16.89% 2

Other funds holding PASG

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Versant Venture Management's PASG Position: Q3 2024 in Review

Versant Venture Management sold out of Passage Bio (PASG) in Q3 2024, closing a stake of 201,321 shares — an estimated $3.2M sold.

Versant Venture Management first reported a position in PASG in Q1 2021 and held it in 14 quarters. The position peaked at $86.7M in Q1 2021. 44 funds tracked by Wall St. Rank hold PASG as of Q3 2024.

  • Versant Venture Management reported no remaining Passage Bio position as of Q3 2024 after selling out during the quarter.
  • Versant Venture Management sold 201,321 Passage Bio shares in Q3 2024, an estimated $3.2M.
  • Versant Venture Management first reported a position in Passage Bio in Q1 2021 and held it in 14 quarters.
  • Versant Venture Management's Passage Bio position peaked at $86.7M in Q1 2021.
  • 44 funds tracked by Wall St. Rank held Passage Bio as of Q3 2024.

Based on Versant Venture Management's 13F filing for Q3 2024, filed 8 Nov 2024.